tiprankstipranks
Advertisement
Advertisement
Edgewise Therapeutics rises 17.5%
PremiumThe FlyEdgewise Therapeutics rises 17.5%
3d ago
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
Premium
The Fly
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
3d ago
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
Premium
The Fly
Servier to acquire Edgewise Therapeutics’ muscular dystrophy business for $2.65B
3d ago
Edgewise Therapeutics reports Q1 EPS (46c), consensus (49c)
PremiumThe FlyEdgewise Therapeutics reports Q1 EPS (46c), consensus (49c)
28d ago
Edgewise Therapeutics price target raised to $52 from $46 at Truist
Premium
The Fly
Edgewise Therapeutics price target raised to $52 from $46 at Truist
28d ago
Edgewise Therapeutics rises 18.1%
Premium
The Fly
Edgewise Therapeutics rises 18.1%
30d ago
JPMorgan ups Edgewise target, adds to Analyst Focus List
PremiumThe FlyJPMorgan ups Edgewise target, adds to Analyst Focus List
3M ago
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors
Premium
Company Announcements
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors
3M ago
Edgewise Therapeutics’ sevasemten shows efficacy in Becker disorder
Premium
The Fly
Edgewise Therapeutics’ sevasemten shows efficacy in Becker disorder
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100